Congenital pain insensitivity (CPI) is an autosomal recessive disorder characterized by the inability to discern physical pain although the ability to feel a stimulus is intact [1]. This rare ailment is considered to be a part of the hereditary sensory and autonomic neuropathies (HSAN) [2]. CPI is a genetically heterogeneous disease caused by mutations in the SCN9A [3], NTRK1 [4], and NGFB genes [5]. If left undetected and unaddressed, this condition can affect the patient's overall health and result in serious outcomes.

The clinical presentation reflects which gene is affected. Generally, the cases demonstrate a lack of pain perception with burns, bone fractures, joint dislocations, and other injuries [6]. Moreover, they engage in self-mutilation by biting on their tongue, lips, and digits [7] [8] resulting in laceration and ulceration of oral mucosa and scarring of the cheeks [9] [10]. Additionally, affected individuals may exhibit mental retardation and developmental delays with varying degrees. Also common are behavioral issues and emotional lability. Furthermore, patients may be prone to developing neurotrophic keratitis, corneal ulcerations and scarring, and even infection.

Depending on the mutated gene and the resultant clinical phenotype, anosmia [2] or anhidrosis [4] [10] are prominent features. The latter predisposes to recurrent febrile episodes [10].

Complications

Painless injuries induce severe consequences such as recurrent disease and repeated fractures. Specifically, sufferers are susceptible to developing osteomyelitis, acroosteolysis, and Charcot joints. Additionally, they may develop oral ulcers and other lesions, which further lead to infections, oral bleeding, and malnutrition [10]. If not treated, poor outcomes such as failure to thrive are likely [10].

Physical exam

The neurologic exam in subjects with CPI reveals normal touch, vibration, and position senses. Remarkable overall findings include joint deformities, disfiguring injuries, oral and eye abnormalities.

Infants and young children with an impaired response to pain and repeated harmful behaviors should be evaluated for this medical entity. The workup will include the patient's history and presentation, a complete physical exam (including a focus on neurologic, oral, and eye tests), and specialized studies.

Diagnostic tests

Biopsy of the skin and nerves can confirm the diagnosis by revealing distinctive findings [11]. Specifically, microscopic analysis of the skin may show the abnormal functioning of nerves innervating eccrine sweat glands while examination of the nerve tissue may demonstrate a diminished quantity of unmyelinated small-diameter fibers. Another exam is characterized by applying pressure with a pen onto the patient's nail bed. Note that an absent withdrawal response is a result of the lack of pain perception [11]. Clinicians may perform the axonal flare test, in which an intradermal histamine injection results in a characteristic skin response. An electromyogram (EMG) will typically yield normal results [1]. Genetic testing is not routinely done since there are many mutations associated with CPI.

The prognosis for individuals with CIP varies. While the condition itself is not life-threatening, the lack of pain sensation can lead to severe injuries and complications. With proper management and preventive measures, many individuals can lead relatively normal lives. However, ongoing medical supervision is essential to address any injuries or complications promptly.

CIP is primarily caused by genetic mutations affecting ion channels, particularly sodium channels involved in transmitting pain signals. The most common gene associated with CIP is SCN9A. These mutations disrupt the normal function of ion channels, preventing the transmission of pain signals to the brain.

CIP is an extremely rare condition, with only a few hundred cases reported worldwide. It affects both males and females equally and is usually identified in early childhood when injuries occur without the expected pain response. Due to its rarity, CIP is often underdiagnosed or misdiagnosed.

The pathophysiology of CIP involves mutations in genes that encode ion channels, particularly those responsible for sodium ion transport. These channels are crucial for the generation and propagation of electrical signals in nerves. In CIP, the mutations lead to a failure in transmitting pain signals from the peripheral nerves to the central nervous system, resulting in insensitivity to pain.

As a genetic disorder, there is no known way to prevent CIP. Genetic counseling may be beneficial for families with a history of the condition to understand the risks and implications. Prenatal testing can also be considered for at-risk pregnancies to identify the presence of genetic mutations associated with CIP.

Channelopathy-Associated Congenital Insensitivity to Pain is a rare genetic disorder characterized by an inability to feel pain due to dysfunctional ion channels. While there is no cure, management focuses on preventing injuries and educating patients and caregivers. Genetic testing plays a crucial role in diagnosis, and ongoing medical supervision is essential to address potential complications.

If you or someone you know has been diagnosed with Channelopathy-Associated Congenital Insensitivity to Pain, it's important to understand the condition and its implications. This disorder means that the usual pain signals that alert us to injury are absent, which can lead to unnoticed harm. Regular medical check-ups and protective measures are vital to prevent injuries. While there is no cure, with proper management, individuals with CIP can lead fulfilling lives. Genetic counseling may be helpful for families to understand the condition better.

1. Peddareddygari LR, Oberoi K, Grewal RP. Congenital Insensitivity to Pain: A Case Report and Review of the Literature. Case Rep Neurol Med. 2014;2014:141953.
2. Genetics Home Reference (GHR). Congenital insensitivity to pain. http://ghr.nlm.nih.gov/condition/congenital-insensitivity-to-pain. Accessed May 22nd, 2017.
3. Cox JJ, Sheynin J, Shorer Z, et al. An SCN9A channelopathy causes congenital inability to experience pain. Hum Mutat. 2010;31(9):E1670-86.
4. Miura Y, Mardy S, Awaya Y, et al. Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor in congenital insensitivity to pain with anhidrosis (CIPA) families. Hum Genet. 2000;106(1):116-24.
5. Carvalho OP, Thornton GK, Hertecant J, et al. A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. J Med Genet. 2011;48(2):131-5.
6. Klein CJ, Wu Y, Kilfoyle DH, et al. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia. J Neurol Neurosurg Psychiatry. 2013;84(4):386-391.
7. Nolano M, Crisci C, Santoro L, et al. Absent innervation of skin and sweat glands in congenital insensitivity to pain with anhidrosis. Clin Neurophysiol. 2000;111(9):1596–601.
8. Kriel RL. Abnormalities of Sensory Perception in the Practice of Pediatric Neurology. Vol 1. In: Swaiman KF, Wright FS, eds. St. Louis, MO: CV Mosby CO; 1982: 222–231.
9. Amano A, Akiyama S, Ikeda M, Morisaki I. Oral manifestations of hereditary sensory and autonomic neuropathy type IV. Congenital insensitivity to pain with anhidrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86(4):425–31.
10. Safari A, Khaledi AA, Vojdani M. Congenital Insensitivity to Pain with Anhidrosis (CIPA): A Case Report. Iran Red Crescent Med J. 2011;13(2):134-138.
11. Zhang S, Malik Sharif S, Chen Y-C, et al. Clinical features for diagnosis and management of patients with PRDM12 congenital insensitivity to pain. J Med Genet. 2016;53(8):533-535.